PMC:7600245 / 7017-7674 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T49","span":{"begin":185,"end":192},"obj":"Body_part"}],"attributes":[{"id":"A49","pred":"fma_id","subj":"T49","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"Collectively, the goal of antiviral therapeutics is to inhibit one or more events in the life cycle of the virus in order to impede the propagation of infection. Along these lines, any protein or event in the virus life cycle can be considered as a molecular target for anti-COVID-19 drug development efforts. In this review, we describe the antiviral agents that are currently being tested in clinical trials to block and/or inhibit the advanced events of the virus life cycle. Although the majority of the presented antiviral therapeutics target the viral polymerase or the viral proteases, few other therapeutics target other molecular targets (Table 1)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T24","span":{"begin":151,"end":160},"obj":"Disease"},{"id":"T25","span":{"begin":275,"end":283},"obj":"Disease"}],"attributes":[{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Collectively, the goal of antiviral therapeutics is to inhibit one or more events in the life cycle of the virus in order to impede the propagation of infection. Along these lines, any protein or event in the virus life cycle can be considered as a molecular target for anti-COVID-19 drug development efforts. In this review, we describe the antiviral agents that are currently being tested in clinical trials to block and/or inhibit the advanced events of the virus life cycle. Although the majority of the presented antiviral therapeutics target the viral polymerase or the viral proteases, few other therapeutics target other molecular targets (Table 1)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T42","span":{"begin":107,"end":112},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T43","span":{"begin":209,"end":214},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T44","span":{"begin":247,"end":248},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T45","span":{"begin":384,"end":390},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T46","span":{"begin":461,"end":466},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"Collectively, the goal of antiviral therapeutics is to inhibit one or more events in the life cycle of the virus in order to impede the propagation of infection. Along these lines, any protein or event in the virus life cycle can be considered as a molecular target for anti-COVID-19 drug development efforts. In this review, we describe the antiviral agents that are currently being tested in clinical trials to block and/or inhibit the advanced events of the virus life cycle. Although the majority of the presented antiviral therapeutics target the viral polymerase or the viral proteases, few other therapeutics target other molecular targets (Table 1)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T50","span":{"begin":26,"end":35},"obj":"Chemical"},{"id":"T51","span":{"begin":185,"end":192},"obj":"Chemical"},{"id":"T52","span":{"begin":284,"end":288},"obj":"Chemical"},{"id":"T53","span":{"begin":342,"end":358},"obj":"Chemical"},{"id":"T54","span":{"begin":518,"end":527},"obj":"Chemical"}],"attributes":[{"id":"A50","pred":"chebi_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A51","pred":"chebi_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A52","pred":"chebi_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A53","pred":"chebi_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A54","pred":"chebi_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"Collectively, the goal of antiviral therapeutics is to inhibit one or more events in the life cycle of the virus in order to impede the propagation of infection. Along these lines, any protein or event in the virus life cycle can be considered as a molecular target for anti-COVID-19 drug development efforts. In this review, we describe the antiviral agents that are currently being tested in clinical trials to block and/or inhibit the advanced events of the virus life cycle. Although the majority of the presented antiviral therapeutics target the viral polymerase or the viral proteases, few other therapeutics target other molecular targets (Table 1)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T50","span":{"begin":0,"end":161},"obj":"Sentence"},{"id":"T51","span":{"begin":162,"end":309},"obj":"Sentence"},{"id":"T52","span":{"begin":310,"end":478},"obj":"Sentence"},{"id":"T53","span":{"begin":479,"end":657},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Collectively, the goal of antiviral therapeutics is to inhibit one or more events in the life cycle of the virus in order to impede the propagation of infection. Along these lines, any protein or event in the virus life cycle can be considered as a molecular target for anti-COVID-19 drug development efforts. In this review, we describe the antiviral agents that are currently being tested in clinical trials to block and/or inhibit the advanced events of the virus life cycle. Although the majority of the presented antiviral therapeutics target the viral polymerase or the viral proteases, few other therapeutics target other molecular targets (Table 1)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"110","span":{"begin":151,"end":160},"obj":"Disease"},{"id":"111","span":{"begin":275,"end":283},"obj":"Disease"}],"attributes":[{"id":"A110","pred":"tao:has_database_id","subj":"110","obj":"MESH:D007239"},{"id":"A111","pred":"tao:has_database_id","subj":"111","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Collectively, the goal of antiviral therapeutics is to inhibit one or more events in the life cycle of the virus in order to impede the propagation of infection. Along these lines, any protein or event in the virus life cycle can be considered as a molecular target for anti-COVID-19 drug development efforts. In this review, we describe the antiviral agents that are currently being tested in clinical trials to block and/or inhibit the advanced events of the virus life cycle. Although the majority of the presented antiviral therapeutics target the viral polymerase or the viral proteases, few other therapeutics target other molecular targets (Table 1)."}